Steve R. Bailey
@Frazier Life Sciences Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$2.495BTotal holdings53
Assets growth rate16.72%Assets growth rate (2-Q avg)3.46%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Frazier Life Sciences Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 53 positions.
Assets under management
The assets under management (AUM) of Frazier Life Sciences Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.495B in assets, with a quarterly growth rate of 16.72% and a 2-quarter average growth rate of 3.46%. The portfolio is managed by Steve R. Bailey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
ARQTArcutis Biotherapeutics Inc
| 3.28% | $81.703M 8.785M shares@ $9.3 avg price | |
EWTXEdgewise Therapeutics Inc
| 3.04% | $75.609M 2.833M shares@ $26.69 avg price | Decreased -24.07% |
ANABAnaptysbio Inc
| 2.97% | $74.008M 2.209M shares@ $33.51 avg price | Increased 2.02% |
ERASErasca Inc
| 2.13% | $52.939M 19.392M shares@ $2.74 avg price | Increased 19.59% |
TARSTarsus Pharmaceuticals Inc
| 2.1% | $52.214M 1.588M shares@ $32.89 avg price | |
AGIOAgios Pharmaceuticals Inc
| 1.86% | $46.392M 1.044M shares@ $44.43 avg price | Increased 19.75% |
RVMDRevolution Medicines Inc
| 1.82% | $45.235M 997,455 shares@ $45.35 avg price | |
SLNOSoleno Therapeutics Inc
| 1.78% | $44.212M 875,667 shares@ $50.5 avg price | |
KALVKalvista Pharmaceuticals Inc
| 1.72% | $42.706M 3.688M shares@ $11.59 avg price | |
ORICOric Pharmaceuticals Inc
| 1.71% | $42.464M 4.143M shares@ $10.26 avg price |